Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Feb 21, 2018)
  • 8-K (Feb 8, 2018)
  • 8-K (Nov 13, 2017)
  • 8-K (Oct 30, 2017)
  • 8-K (Oct 24, 2017)
  • 8-K (Sep 7, 2017)

 
Other

MediciNova 8-K 2005

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Graphic
  4. Graphic
Form 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 7, 2005

 


 

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware   000-51133   33-0927979
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

4350 La Jolla Village Drive, Suite 950

San Diego, CA 92122

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (858) 373-1500

 

Not Applicable

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 

1


Item 8.01 Other Events.

 

On September 7, 2005, MediciNova, Inc. (the “Company”) announced in a press release the completion of patient enrollment in a Phase II clinical study with MN-001 for the treatment of asthma.

 

Attached as Exhibit 99.1 hereto and incorporated herein by reference in its entirety is the press release issued by the Company on September 7, 2005.

 

Item 9.01 Financial Statements and Exhibits.

 

(c) Exhibits.

 

Exhibit    

  

Description    


99.1    Press Release issued September 7, 2005.

 

2


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 7, 2005.

 

MEDICINOVA, INC.

By:  

/s/ Takashi Kiyoizumi

   

Takashi Kiyoizumi, M.D., Ph.D.

President and Chief Executive Officer

 

3


EXHIBIT INDEX

 

Exhibit No.    

  

Description    


99.1    Press Release issued September 7, 2005.

 

4

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki